The U.S. Department of Commerce’s National Institute of Standards and Technology – NIST – has made two awards totaling $153 million to the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). The awards were announced yesterday by U.S. Secretary of Commerce Gina Raimondo at the NIIMBL annual meeting in Washington, D.C.
NIIMBL* will work to increase the shelf life and reduce the amount of refrigeration required for messenger RNA vaccines, boost capabilities for rapid production of antigens used in testing and screening for new variants and develop novel technologies for detecting counterfeit vaccines, among other things.
Secretary Raimondo was joined at the NIIMBL meeting by Senator Chris Coons of Delaware, Acting Commissioner of the Food and Drug Administration Janet Woodcock and Director of the FDA’s Center for Biologics Evaluation and Research Peter Marks. “This important investment for America, funded in part by President Biden’s American Rescue Plan, will help meet the nation’s need for lifesaving biopharmaceuticals,” said Raimondo
The first award renews NIST’s federal sponsorship of NIIMBL, providing $70 million over five years with an equal, non-federal cost-matching requirement. This award will allow NIIMBL to continue work with “domestic biopharmaceutical manufacturing by developing flexible, agile and cost-effective manufacturing processes that can be scaled up quickly and are less reliant on foreign supply chains.”
NIST will also provide $83 million to NIIMBL over three years from the American Rescue Plan to support research and development to prevent, prepare for and respond to coronavirus outbreaks.
During the COVID-19 pandemic, scientific and manufacturing innovation delivered vaccines in record time under Operation Warp Speed, which produced the vaccines that ex-president Trump and family as well as friends took. The new funding will enable NIIMBL efforts “to help transform this emergency response into a sustainable, ongoing effort to address the continuing coronavirus threat. NIIMBL will do this by developing efficient, robust processes for manufacturing vaccines and therapeutics for COVID-19 and other coronavirus strains that could emerge in the future.”
NIIMBL works on challenges that are too big for any single organization to address. The institute brings together more than 180 members, including biopharmaceutical and biotechnology companies, raw materials suppliers, equipment and product manufacturers, academic research institutions, state governments and nonprofit organizations focused on global health initiatives and workforce development. Every $1 of federal investment in NIIMBL has been matched by $1.80 in funding from NIIMBL member organizations.
Commerce said since NIIMBL was launched in 2017, its efforts have led to better diagnostic testing and plasma donor screening, an injectable antibody therapeutic that reduces the need for intravenous administration, and improved supply chain models for meeting surging demand during COVID outbreaks. The institute’s website.
The Manufacturing USA institutes and their sponsors, the U.S. Departments of Commerce, Defense and Energy, connect more than 2,000 organizations across hundreds of major projects to quickly move technology from laboratory prototypes to industrial capabilities and provide thousands of people with advanced manufacturing knowledge and skills. To learn more about Manufacturing USA, visit www.ManufacturingUSA.com. NIST promotes U.S. innovation and industrial competitiveness by advancing measurement science, standards and technology in ways that enhance economic security and improve our quality of life. To learn more about NIST, visit NIST.gov or National Institute of Standards and Technology
*NIIMBL is a public-private partnership designed to accelerate innovation in the U.S. biopharmaceutical industry, which produces vaccines, monoclonal antibodies, gene therapies and other medical products derived from biological sources. NIIMBL is a Manufacturing USA institute sponsored by the Department of Commerce.
About Ken Zino
Ken Zino, publisher (kzhw@aol.com), is a versatile auto industry participant with global experience spanning decades in print and broadcast journalism, as well as social media. He has automobile testing, marketing, public relations and communications experience. He is past president of The International Motor Press Assn, the Detroit Press Club, founding member and first President of the Automotive Press Assn. He is a member of APA, IMPA and the Midwest Automotive Press Assn.
Zino is at home on test tracks, knows his way around U.S. Congressional hearing rooms, auto company headquarters, plant floors, as well as industry research and development labs where the real mobility work is done. He can quote from court decisions, refer to instrumented road tests, analyze financial results, and profile executive personalities and corporate cultures.
He also brings an historical perspective while citing their contemporary relevance of the work of legendary auto writers such as Ken Purdy, Jim Dunne or Jerry Flint, or writers such as Red Smith, Mark Twain, Thomas Jefferson – all to bring perspective to a chaotic automotive universe.
Above all, decades after he first drove a car, Zino still revels in the sound of the exhaust as the throttle is blipped and the driver’s rush that occurs when the entry, apex and exit points of a turn are smoothly and swiftly crossed. It’s the beginning of a perfect lap.
AutoInformed has an editorial philosophy that loves transportation machines of all kinds while promoting critical thinking about the future use of cars and trucks.
Zino builds AutoInformed from his background in automotive journalism starting at Hearst Publishing in New York City on Motor and MotorTech Magazines and car testing where he reviewed hundreds of vehicles in his decade-long stint as the Detroit Bureau Chief of Road & Track magazine. Zino has also worked in Europe, and Asia – now the largest automotive market in the world with China at its center.
Covid – Commerce NIST Grant of $153 million to National Institute for Innovation in Manufacturing Biopharmaceuticals
The U.S. Department of Commerce’s National Institute of Standards and Technology – NIST – has made two awards totaling $153 million to the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). The awards were announced yesterday by U.S. Secretary of Commerce Gina Raimondo at the NIIMBL annual meeting in Washington, D.C.
NIIMBL* will work to increase the shelf life and reduce the amount of refrigeration required for messenger RNA vaccines, boost capabilities for rapid production of antigens used in testing and screening for new variants and develop novel technologies for detecting counterfeit vaccines, among other things.
Secretary Raimondo was joined at the NIIMBL meeting by Senator Chris Coons of Delaware, Acting Commissioner of the Food and Drug Administration Janet Woodcock and Director of the FDA’s Center for Biologics Evaluation and Research Peter Marks. “This important investment for America, funded in part by President Biden’s American Rescue Plan, will help meet the nation’s need for lifesaving biopharmaceuticals,” said Raimondo
The first award renews NIST’s federal sponsorship of NIIMBL, providing $70 million over five years with an equal, non-federal cost-matching requirement. This award will allow NIIMBL to continue work with “domestic biopharmaceutical manufacturing by developing flexible, agile and cost-effective manufacturing processes that can be scaled up quickly and are less reliant on foreign supply chains.”
NIST will also provide $83 million to NIIMBL over three years from the American Rescue Plan to support research and development to prevent, prepare for and respond to coronavirus outbreaks.
During the COVID-19 pandemic, scientific and manufacturing innovation delivered vaccines in record time under Operation Warp Speed, which produced the vaccines that ex-president Trump and family as well as friends took. The new funding will enable NIIMBL efforts “to help transform this emergency response into a sustainable, ongoing effort to address the continuing coronavirus threat. NIIMBL will do this by developing efficient, robust processes for manufacturing vaccines and therapeutics for COVID-19 and other coronavirus strains that could emerge in the future.”
NIIMBL works on challenges that are too big for any single organization to address. The institute brings together more than 180 members, including biopharmaceutical and biotechnology companies, raw materials suppliers, equipment and product manufacturers, academic research institutions, state governments and nonprofit organizations focused on global health initiatives and workforce development. Every $1 of federal investment in NIIMBL has been matched by $1.80 in funding from NIIMBL member organizations.
Commerce said since NIIMBL was launched in 2017, its efforts have led to better diagnostic testing and plasma donor screening, an injectable antibody therapeutic that reduces the need for intravenous administration, and improved supply chain models for meeting surging demand during COVID outbreaks. The institute’s website.
The Manufacturing USA institutes and their sponsors, the U.S. Departments of Commerce, Defense and Energy, connect more than 2,000 organizations across hundreds of major projects to quickly move technology from laboratory prototypes to industrial capabilities and provide thousands of people with advanced manufacturing knowledge and skills. To learn more about Manufacturing USA, visit www.ManufacturingUSA.com. NIST promotes U.S. innovation and industrial competitiveness by advancing measurement science, standards and technology in ways that enhance economic security and improve our quality of life. To learn more about NIST, visit NIST.gov or National Institute of Standards and Technology
*NIIMBL is a public-private partnership designed to accelerate innovation in the U.S. biopharmaceutical industry, which produces vaccines, monoclonal antibodies, gene therapies and other medical products derived from biological sources. NIIMBL is a Manufacturing USA institute sponsored by the Department of Commerce.
About Ken Zino
Ken Zino, publisher (kzhw@aol.com), is a versatile auto industry participant with global experience spanning decades in print and broadcast journalism, as well as social media. He has automobile testing, marketing, public relations and communications experience. He is past president of The International Motor Press Assn, the Detroit Press Club, founding member and first President of the Automotive Press Assn. He is a member of APA, IMPA and the Midwest Automotive Press Assn. Zino is at home on test tracks, knows his way around U.S. Congressional hearing rooms, auto company headquarters, plant floors, as well as industry research and development labs where the real mobility work is done. He can quote from court decisions, refer to instrumented road tests, analyze financial results, and profile executive personalities and corporate cultures. He also brings an historical perspective while citing their contemporary relevance of the work of legendary auto writers such as Ken Purdy, Jim Dunne or Jerry Flint, or writers such as Red Smith, Mark Twain, Thomas Jefferson – all to bring perspective to a chaotic automotive universe. Above all, decades after he first drove a car, Zino still revels in the sound of the exhaust as the throttle is blipped and the driver’s rush that occurs when the entry, apex and exit points of a turn are smoothly and swiftly crossed. It’s the beginning of a perfect lap. AutoInformed has an editorial philosophy that loves transportation machines of all kinds while promoting critical thinking about the future use of cars and trucks. Zino builds AutoInformed from his background in automotive journalism starting at Hearst Publishing in New York City on Motor and MotorTech Magazines and car testing where he reviewed hundreds of vehicles in his decade-long stint as the Detroit Bureau Chief of Road & Track magazine. Zino has also worked in Europe, and Asia – now the largest automotive market in the world with China at its center.